Health Condition 1: A920- Chikungunya virus disease
Conditions
Interventions
Intervention1: Shallakyadi capsule: The patients will be given Shallakyadi capsule for a period of 8 weeks
Control Intervention1: Not applicable: Not applicable
Sponsors
Institute of Teaching and Research in Ayurveda
Eligibility
Inclusion criteria
Inclusion criteria: Confirm case of Chikungunya fever with symptoms of pCHIK-CIR Patient willing to participate in the trial
Exclusion criteria
Exclusion criteria: Age below 18 years & above 60 years. Pregnant and lactating women History of RA, Gout, Psoriatic arthritis, rheumatic fever, autoimmune disease, thyroid dysfunction, sarcoidosis, SLE before Chikungunya fever. Patients suffering from: Malignant and accelerated hypertension, coronary artery disease, uncontrolled diabetes. Patient undergoing regular treatment for any other severe illness and also patients suffering from pulmonary tuberculosis or bone tuberculosis, carcinoma and HIV positive patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the trial drug will reduce the inflammation and pain through correcting underlined pathogenesis and so that it will become possible to manage Post - Chikungunya Chronic Inflammatory Rheumatism(pCHIK-CIR)Timepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The drug will improve the quality of life in patient of Post-Chikungunya Chronic Inflammatory RheumatismTimepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactMandip Goyal
Institiute of Teaching and Research in Ayurveda, Jamnagar
Outcome results
None listed